 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19827 News |  |
| «12345678910111213...203204» |
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Contrast enhanced endoscopic ultrasound detects early therapy response following anti-TNF-therapy in patients with ulcerative colitis. (Pubmed Central) - Aug 6, 2024
dCEUS enables the early detection of therapy response in patients with aUC, which serves as a predictive marker for long-term clinical success. Therefore, dCEUS serves as a diagnostic tool for assessing the probability of future therapy success.
- | Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Journal: Complex Presentation of Multicentric Castleman Disease with Coexisting HIV, HHV-8, and Other Opportunistic Infections. (Pubmed Central) - Aug 6, 2024
His treatment included chemotherapy with doxorubicin and rituximab while continuing his anti-Tb and antiretroviral therapy. This complex case highlights the diagnostic challenges of managing CD in the presence of multiple coexisting conditions, emphasizing the need for comprehensive evaluation in complex clinical presentations.
- | Humira (adalimumab) / AbbVie
Journal: Therapeutic Outcomes of Non-Infectious Scleritis Treated with Tumor Necrosis Factor-Alpha Inhibitors. (Pubmed Central) - Aug 5, 2024
There was no significant difference between the baseline and 6-month BCVA (p?=?0.52). TNF inhibitors are an effective scleritis therapy with significant systemic corticosteroid sparing effect.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Long-term Experience with Anti-tumor Necrosis factor- ? Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis. (Pubmed Central) - Aug 5, 2024
TNF inhibitors are an effective scleritis therapy with significant systemic corticosteroid sparing effect. In patients treated with adalimumab, the mean time to prednisone dose ?7.5 mg/day was 4.02
- | Journal: The Role of Biologic Agents in the Management of Pediatric-Onset Noninfectious Posterior Scleritis. (Pubmed Central) - Aug 5, 2024
Five patients (9 eyes) treated with adalimumab, infliximab, abatacept and secukinumab were included. Mean BCVA was 0.83 (range 0.3-1.0) at baseline and 1.0 for all eyes after 12
- | Humira (adalimumab) / AbbVie
Journal: Effect Of Adalimumab Treatment On ?nflammatory And Hematological Parameters ?n Patients With Hidradenitis Suppurativa. (Pubmed Central) - Aug 5, 2024
Adalimumab treatment has not had a significant effect on systemic inflammation markers in HS, an inflammatory disease. More studies are needed to evaluate the effect of adalimumab on these markers in HS.
- | Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Journal, Real-world evidence, Real-world: Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn's Disease: Results From the EVOLVE Study. (Pubmed Central) - Aug 5, 2024
More studies are needed to evaluate the effect of adalimumab on these markers in HS. In a real-world setting, biologic-naive patients with CD treated with vedolizumab demonstrated a greater likelihood of drug persistence and achieving clinical remission, with equivalent rates of response and mucosal healing versus adalimumab-treated patients.
- || Clinical, Review, Journal: Treatment of Hailey-Hailey disease with biologics and small molecule inhibitors: a systematic review. (Pubmed Central) - Aug 4, 2024
However, some patients experienced recurrences. In conclusion, biologics and small molecule inhibitors may offer a treatment alternative for refractory HHD patients, but further confirmation is necessary through large-scale randomized controlled clinical trials.
- | Retrospective data, Journal, Metastases: Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-na (Pubmed Central) - Aug 2, 2024
Furthermore, these treatments demonstrated lower rates of discontinuation compared to other study drugs included in the analysis. Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates.
- ||| Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
P3 data, Journal, HEOR, Patient reported outcomes: Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials. (Pubmed Central) - Aug 1, 2024
Understanding the balance between efficacy and feasibility in treatment decisions is crucial, as feasibility may impact persistency outcomes and potentially increase persistency rates. Patients with PsA who achieve clinical disease control are more likely to achieve improvements and normative values in PROs and QoL measures, which reinforces disease control as a treatment target.
- | Humira (adalimumab) / AbbVie
Journal: Ultrasound transmural healing correlates with higher adalimumab drug concentration in Crohn's disease only in the short-term. (Pubmed Central) - Aug 1, 2024
Higher adalimumab through levels were corelated with transmural healing with ultrasound during the first year of treatment. This correlation was not found after one year of treatment.
- || Review, Journal: A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo. (Pubmed Central) - Aug 1, 2024
Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD. (Pubmed Central) - Jul 31, 2024
Overweight/obese children with IBD were not at a higher risk of LOR to anti-TNF. Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up.
- | Tremfya (guselkumab) / J&J
Journal, Real-world evidence, Real-world: Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. (Pubmed Central) - Jul 31, 2024
Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up. This real-world study employing US commercial health-plan claims data to assess on-label treatment persistence in PsA demonstrated that, at 12 months, guselkumab was associated with a 3 times greater likelihood of persistence compared with SC TNFi.
- | Journal: Network-Based Drug Repurposing and Genomic Analysis to Unveil Potential Therapeutics for Monkeypox Virus. (Pubmed Central) - Jul 31, 2024
In addition, the pharmacophore-based screening identified a molecule that is comparable to Baricitinib and has the potential to be effective against MPXV. The findings of the study suggest that ZINC22060520 is a promising medication for treating MPXV infection and proposes these medications as potential options for additional experimental and clinical assessment in the battle against MPXV.
- ||| Bimzelx (bimekizumab) / UCB
P3 data, Journal: Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies. (Pubmed Central) - Jul 30, 2024
P3
The findings of the study suggest that ZINC22060520 is a promising medication for treating MPXV infection and proposes these medications as potential options for additional experimental and clinical assessment in the battle against MPXV. Treatment with bimekizumab demonstrated consistent, sustained efficacy to 52 weeks in bDMARD-na
- Humira (adalimumab) / AbbVie
PERSONALIZED IMMUNOMODULATORY DRUG REPURPOSING IN MUCOPOLYSACCHARIDOSES (Poster Room | Level 0) - Jul 30, 2024 - Abstract #SSIEM2024SSIEM_494;
The results will be integrated into the tool to improve its performance. So far, our tool can be used for paediatric and adult patients with MPS I, II, III, IV, VI, VII and IX and covers four immunomodulators.
- || Retrospective data, Review, Journal: Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU). (Pubmed Central) - Jul 29, 2024
So far, our tool can be used for paediatric and adult patients with MPS I, II, III, IV, VI, VII and IX and covers four immunomodulators. Biological treatment adjustments are frequent in moderate-to-severe psoriasis; flexible dosing regimens would support optimal management.
- | Humira (adalimumab) / AbbVie
Journal: Colonic Mucormycosis in Fistulizing Crohn's Disease. (Pubmed Central) - Jul 29, 2024
We present a case of a middle-aged female with perianal Crohn's disease on adalimumab who developed colonic mucormycosis causing a flare in her disease activity. This patient highlights the need to increase awareness about fungal infections as a cause of disease flare in inflammatory bowel disease.
- || Retrospective data, Review, Journal: Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis. (Pubmed Central) - Jul 29, 2024
Moreover, a network meta-analysis indicated that certolizumab pegol and infliximab were associated with a higher risk of serious infection compared to other TNF inhibitors...For patients at a heightened risk of infection, prioritizing the use of etanercept and golimumab may be advisable to minimize patient risk. Systematic Review Registration: identifier CRD42022316577.
- || Humira (adalimumab) / AbbVie
P1 data, Journal: Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm phase I trial. (Pubmed Central) - Jul 28, 2024
P1
Systematic Review Registration: identifier CRD42022316577. VOLTAIRE-HCLF compared the relative bioavailability of citrate-free high-concentration and reference formulations of the biosimilar adalimumab-adbm (Cyltezo
- || Review, Journal: Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review. (Pubmed Central) - Jul 27, 2024
However, due to the complex molecular nature of wound healing, no single target molecule can be identified. Therefore, the use of mAbs should be considered as a translational approach for limited cases of multi-resistant conditions.
- || Bimzelx (bimekizumab) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Review, Journal: Hidradenitis Suppurativa: New Targets and Emerging Treatments. (Pubmed Central) - Jul 27, 2024
Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics-adalimumab, secukinumab, and bimekizumab-have received US Food and Drug Administration (FDA) or European Medicines Evaluation Agency approval for treating HS. Promising agents under investigation are targeting interleukin 17A/F, JAK/STAT pathway, interleukin 36, interleukin 1, and more.
- | Humira (adalimumab) / AbbVie
Journal, Immunomodulating: A case of AZOOR under immunomodulatory treatment. (Pubmed Central) - Jul 27, 2024
Complete diagnostic work-up is important to rule out other etiologies. Due to the lack of randomized controlled trials, therapeutic decisions obligatorily rely on empiric treatment decisions in combination with frequent follow-up examinations.
- || Review, Journal: Management of JIA associated uveitis. (Pubmed Central) - Jul 26, 2024
Current international recommendations advise a step-wise approach, starting with methotrexate and moving on to adalimumab if methotrexate alone is not sufficient to control the disease. If the uveitis remains active despite standard treatment other therapeutic options may be considered including anti-IL6 or other anti-TNF agents such as infliximab, although the evidence for these agents is limited.
- || Rinvoq (upadacitinib) / AbbVie
Retrospective data, Review, Journal: Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety. (Pubmed Central) - Jul 26, 2024
Upadacitinib exhibited satisfactory efficacy in treating axial spondyloarthritis, reducing disease activity and significantly enhancing patients' physical function, emotional well-being, and social engagement. This meta-analysis offers robust evidence supporting upadacitinib as a new treatment for axial spondyloarthritis patients.
- || Review, Journal: The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. (Pubmed Central) - Jul 24, 2024
However, surgical interventions are necessary for complex cases or intra-abdominal complications. Setons and LIFT procedures are the most common surgical options.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: TNF-alpha blockade in Primary Chronic Non-Bacterial Osteomyelitis of the Mandible. (Pubmed Central) - Jul 23, 2024
Our results suggest that blocking TNF-? is efficient and safe in CNOM.
- || Bimzelx (bimekizumab) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Review, Journal: Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. (Pubmed Central) - Jul 23, 2024
The three approved biologics for treating HS include adalimumab, secukinumab and bimekizumab; the benefits and concerns of biologics in everyday clinical practice are detailed. In summary, this review serves as a HS management guide for GPs, with a particular focus on the biologic treatment landscape.
- || Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal: What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022. (Pubmed Central) - Jul 23, 2024
For patients reaching low disease activity and remission, TDM can help successful dose reduction, while it cannot inform the successful drug discontinuation. However, existing trials are limited, and more well-designed trials are necessary to clarify the role of TDM in adalimumab treatment.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Biologic treatment sequences in moderate-to-severe psoriasis. (Pubmed Central) - Jul 23, 2024
However, existing trials are limited, and more well-designed trials are necessary to clarify the role of TDM in adalimumab treatment. This study demonstrates an increased uptake of more novel biologics as they become available, due to improved safety profiles and clinical outcomes.
- ||| Bimzelx (bimekizumab) / UCB
P3 data, Journal: Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. (Pubmed Central) - Jul 21, 2024
This study demonstrates an increased uptake of more novel biologics as they become available, due to improved safety profiles and clinical outcomes. Rates of hepatic adverse events (AEs) with bimekizumab were consistent through 2
- | Humira (adalimumab) / AbbVie
Journal, Surgery: Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan. (Pubmed Central) - Jul 20, 2024
However, our study was limited by its retrospective nature and the lack of a control group. Despite these limitations, our study revealed the benefits of integrating adalimumab with suitable surgical procedures in managing patients experiencing moderate to severe HS in real-world scenarios.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Frequency of use and annual costs of biological therapy for psoriasis in Colombia in 2019. (Pubmed Central) - Jul 20, 2024
This is the first study to describe the use and cost of biological therapy for psoriasis in Colombia. It provides valuable cost-awareness information for the Colombian health system.
- | Humira (adalimumab) / AbbVie
Journal: Intermediate uveitis in common variable immunodeficiency (CVID) associated with a heterozygous variant in the TNFRSF13B gene. (Pubmed Central) - Jul 19, 2024
It provides valuable cost-awareness information for the Colombian health system. This report of CVID-associated intermediate uveitis in a patient with a heterozygous TNFRSF13B variant highlights the potential involvement of the eye within CVID-associated autoimmunity and the role for anti-TNF blockade in this challenging group of patients.
- ||| Journal, Adverse events, Real-world evidence, Real-world: Safety of TNF-? inhibitors: A real-world study based on the US FDA Adverse Event Reporting System Database. (Pubmed Central) - Jul 19, 2024
The analysis indicates that infliximab is associated with 60 unique positive ADEs, including Hodgkin's disease, metastatic neoplasm, and non-Hodgkin's lymphoma; therefore, these patients should use infliximab with greater caution. Similarly, certolizumab should be used with increased caution in pregnant and postpartum women.
- | Humira (adalimumab) / AbbVie
Journal: Adalimumab induced psoriasis in a Crohn's disease patient: A case report. (Pubmed Central) - Jul 19, 2024
This eruption resisted complete clearance with various potent corticosteroids. The patient was referred back to the treating rheumatologist to possibly change adalimumab to another type of therapy.
- || Retrospective data, Review, Journal: To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF. (Pubmed Central) - Jul 19, 2024
23 articles were eligible, reporting 150 children of whom 109 switched anti-TNF (45 adalimumab, 49 infliximab, 9 golimumab) and 41 swapped to another biologics (31 abatacept, 8 tocilizumab and 1 rituximab). We evaluated a superiority of tocilizumab and infliximab compared to the other drugs(?2 27.5 p
- | Humira (adalimumab) / AbbVie
Journal: Isolated cardiac sarcoidosis presenting as transient ischemic attack. (Pubmed Central) - Jul 18, 2024
In conclusion, this case highlights the need to consider CS as a potential cause of cerebrovascular ischemic events in patients with few stroke risk factors but findings indicative of cardiac disease. It is essential to further explore the mechanisms behind these events and develop treatments that target their causes in this patient population.
- || Review, Journal: (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. (Pubmed Central) - Jul 17, 2024
It is essential to further explore the mechanisms behind these events and develop treatments that target their causes in this patient population. (Re-)initiation of TNF antagonists and JAK inhibitors may be relatively safe in patients with current or previous TB and the need for further treatment of underlying diseases.
- | Humira (adalimumab) / AbbVie
Journal: Multiple sclerosis associated with adalimumab use in ankylosing spondylitis. (Pubmed Central) - Jul 17, 2024
(Re-)initiation of TNF antagonists and JAK inhibitors may be relatively safe in patients with current or previous TB and the need for further treatment of underlying diseases. No abstract available
- | Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment. (Pubmed Central) - Jul 17, 2024
Clinical presentation of the local paediatric uveitis differs from previously described features in Caucasian and other populations. According to our experience as a tertiary eye centre, Beh
- | tofacitinib / Generic mfg.
Journal: A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report. (Pubmed Central) - Jul 17, 2024
Subsequent use of adalimumab and secukinumab resulted in worsening skin rash, prompting a switch to tofacitinib, leading to a remarkable improvement in pustular eruptions after 20 days of treatment. This case demonstrates successful application of tofacitinib in treating severe keratoderma blennorrhagicum refractory to conventional DMARDs and biologics, offering insights into JAK inhibition for challenging rheumatic diseases with skin involvement.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Plasma Cytokines for the Prediction of the Effectiveness of TNF? Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. (Pubmed Central) - Jul 13, 2024
The baseline levels of VEGF, sCD40L, and ICAM1, as well as IL20, could serve as potential predictors of treatment effectiveness using TNFa inhibitors. However, this hypothesis requires confirmation with a larger patient population.
- | Humira (adalimumab) / AbbVie
Journal: Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India. (Pubmed Central) - Jul 11, 2024
Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. (Pubmed Central) - Jul 10, 2024
P=N/A
The drug is safe and well tolerated. Both IFX and ADA have a good safety profile and deliver a beneficial clinical and laboratory response in moderate-severe IBD patients.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists. (Pubmed Central) - Jul 10, 2024
While there are some common trends in the practice patterns for the diagnosis and treatment of patients with VKH, there was no clear consensus on the topic of IMT. There was a slight preference among uveitis specialists to use both IMT and systemic corticosteroids for the first episode of acute VKH.
- || Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal: Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Systemic Review and Network Meta-analysis. (Pubmed Central) - Jul 9, 2024
Tofacitinib, accelerated IFX, standard IFX, and tacrolimus significantly reduced the colectomy rates in SR ASUC patients compared with placebo. Thus, advanced therapies should be considered for rescue therapies in patients with SR ASUC.
- | Avastin (bevacizumab) / Roche, Humira (adalimumab) / AbbVie, Ilaris (canakinumab) / Novartis
Journal: Prediction of human serum concentration-time profiles of therapeutic monoclonal antibodies using common marmosets (Callithrix jacchus): Initial assessment with canakinumab, adalimumab, and bevacizumab. (Pubmed Central) - Jul 8, 2024
As a result, the observed human serum concentration-time curves of the three mAbs following intravenous administration and those of canakinumab and adalimumab following subcutaneous injections (with an assumed absorption rate constant and bioavailability) were reasonably predicted.4. Although further prediction studies using a sufficient number of other mAbs are necessary to evaluate the versatility of this model, the findings indicate that marmosets can be an alternative to preceding animals for human pharmacokinetic predictions of therapeutic mAbs.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: A case of juvenile-onset ankylosing spondylitis effectively treated with tumour necrosis factor-alpha inhibitor agents. (Pubmed Central) - Jul 8, 2024
The bath ankylosing spondylitis disease activity index (BASDAI) value was 8.0 at the time of induction and 3.1 at 6?months after the introduction of adalimumab (at a dose of 40?mg)...The BASDAI value was 2.6 at 6?months, 2.7 at 1?year, and 1.8 at 1.5?years after the introduction of infliximab, indicating that the patient had progressed well without any adverse events...TNF inhibitors were effective in treating juvenile ankylosing spondylitis in the present case without any adverse events. This case is notable because juvenile onset ankylosing spondylitis is one of the reasons for severe lumbago since childhood and because TNF inhibitors were administered promptly after diagnosis.